Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00738140 · ClinicalTrials.gov registry record · Phase 2
Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00738140: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00738140 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00738140, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to discover if intensive lifestyle changes (such as diet and increased physical activity) improve the body's sensitivity to insulin, and therefore help prevent diabetes and other cardiovascular disease, in men receiving GnRH hormone therapy for prostate cancer.
Interventions
- BEHAVIORAL Diabetes Prevention Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-09 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00738140
The ClinicalTrials.gov registry entry for NCT00738140 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Diabetes Prevention Program is the first listed.
NCT00738140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00738140 about?
NCT00738140 is a clinical study titled "Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors". The purpose of this study is to discover if intensive lifestyle changes (such as diet and increased physical activity) improve the body's sensitivity to insulin, and therefore help prevent diabetes and other cardiovascular disease, in men receiving GnRH hormone therapy for prostate cancer.
What is the current status of trial NCT00738140?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2007-09. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00738140?
The interventions under investigation include: Diabetes Prevention Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT00738140?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.